Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

E.S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Ticiana Leal, J.E. Dowell, Ming-Hung Tsai, Christopher Dakhil, Philip J. Stella, Vincent K. Shen, Sylvia Hu,

Annals of Oncology · 2018 · 62 citations · 0 references

DOIFull text

Open access

Concepts